Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: Clinical features and course of M-bcr negative and M-bcr positive CML

A. Dobrovic, A. A. Morley, R. Seshadri, E. H. Januszewicz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The Philadelphia chromosome (Ph) is the cytogenetic hall-mark of chronic myeloid leukemia (CML) and as such has been used to confirm the diagnosis of CML based on morphological and clinical criteria. We have investigated 12 patients who were considered to have clinical and morphological features of CML and who did not have detectable abnormalities of chromosomes 9q34 or 22q11. In six of the 12 patients, rearrangement within the 5.8 kb major breakpoint region (M-bcr) and amplification of CML specific M-bcr-ABL cDNA sequences by the polymerase chain reaction (PCR) was demonstrated. Six other CML patients did not have rearrangement of the M-bcr gene or amplification of BCR-ABL by PCR. These patients had atypical CML. They were significantly older, most had less than 10% immature granulocytic cells (metamyelocytes, myelocytes and promyelocytes) and had various degrees of marrow fibrosis. Three of these six patients died of blastic transformation at 4, 15 and 54 months from diagnosis.

Original languageEnglish
Pages (from-to)187-190
Number of pages4
JournalLeukemia
Volume5
Issue number3
Publication statusPublished - Mar 1991
Externally publishedYes

Fingerprint Dive into the research topics of 'Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: Clinical features and course of M-bcr negative and M-bcr positive CML'. Together they form a unique fingerprint.

Cite this